(R)-1-(2-fluoropyridin-3-yl)ethan-1-ol | 2227811-28-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (R)-1-(2-fluoropyridin-3-yl)ethan-1-ol
• 英文别名: (R)-1-(2-Fluoropyridin-3-yl)ethanol；(1R)-1-(2-fluoropyridin-3-yl)ethanol
• CAS: 2227811-28-9
• 化学式: C₇H₈FNO
• 分子量: 141.145
• InChiKey: JUYIDKNNTBXRHG-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-氯-1H-吡唑并[3,4-B]吡嗪 、 (R)-1-(2-fluoropyridin-3-yl)ethan-1-ol 在 偶氮二甲酸二异丙酯 、 [(2-di-tert-butylphosphino-3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1’-biphenyl)-2-(2’-amino-1,1‘-biphenyl)]palladium(II) methanesulfonate 、 potassium acetate 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 (S)-N-(5-(difluoromethoxy)-1H-pyrazol-3-yl)-1-(1-(2-fluoropyridin-3-yl)ethyl)-1H-pyrazolo[3,4-b]pyrazin-6-amine
  参考文献：
  名称：

  [EN] CDK2 INHIBITORS
  [FR] INHIBITEURS DE CDK2

  摘要：

  The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

  公开号：

  WO2023278326A1

文献信息

• LPA RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Gilead Sciences, Inc.

  公开号：US20210380561A1

  公开（公告）日：2021-12-09

  The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).

  本公开涉及一般与结合溶血磷脂酸受体1（LPAR1）并作为LPAR1的拮抗剂的化合物有关。本公开进一步涉及利用这些化合物制备药物以治疗通过结合LPAR1引起的疾病和/或病况，包括纤维化和非酒精性脂肪性肝炎（NASH）等肝病。
• TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Gilead Sciences, Inc.

  公开号：US20210171500A1

  公开（公告）日：2021-06-10

  The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
• CDK2 INHIBITORS
  申请人：[en]BLUEPRINT MEDICINES CORPORATION

  公开号：WO2024148087A1

  公开（公告）日：2024-07-11

  The present disclosure provides, in part, a compound represented by structural Formula (I): (I), or a pharmaceutically acceptable salt thereof useful for treating a cancer.